Brought to you by 
BMS sells 15% of Mead through IPO that nets $684mm
18 Mar 2009
Executive Summary
Keeping up with plans to limit resources on its non-pharmaceutical assets, Bristol-Myers Squibb has sold about 15% of Mead Johnson Nutrition in an IPO. BMS netted $684mm from 30mm Mead shares at $24 each, the high end of the $21-24 anticipated range. In early February it had planned to offer 25mm shares.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Financing
- IPO
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS sells 15% of Mead through IPO that nets $684mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice